Costs and management of patients with hemophilia A in France: the Hemraude study.

C LaurendeauJ GoudemandM TrossaertB PolackR VarinC GodardF HadimBruno Detournay

Published in: The European journal of health economics : HEPAC : health economics in prevention and care (2021)

Direct costs of HA treatments for HA may be very high especially in the small percentage of patients developing inhibitors or treated with ITI protocol.

Keyphrases

newly diagnosed
end stage renal disease
ejection fraction
chronic kidney disease
randomized controlled trial
prognostic factors